IRIS
TROIANI, Teresa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 13.201
NA - Nord America 6.598
AS - Asia 5.604
SA - Sud America 841
Continente sconosciuto - Info sul continente non disponibili 518
AF - Africa 83
OC - Oceania 21
Totale 26.866
Salva come PNG Salva come JPEG
Nazione #
RU - Federazione Russa 8.742
US - Stati Uniti d'America 6.465
SG - Singapore 1.937
IE - Irlanda 1.236
CN - Cina 1.193
IT - Italia 1.058
HK - Hong Kong 866
VN - Vietnam 683
BR - Brasile 679
DE - Germania 462
GB - Regno Unito 445
UA - Ucraina 353
KR - Corea 316
FR - Francia 269
IN - India 158
FI - Finlandia 139
SE - Svezia 126
JP - Giappone 118
GR - Grecia 109
TR - Turchia 90
CA - Canada 81
NL - Olanda 70
AR - Argentina 60
BD - Bangladesh 47
PK - Pakistan 43
AT - Austria 35
MX - Messico 35
BE - Belgio 31
EC - Ecuador 31
ID - Indonesia 30
PL - Polonia 29
ES - Italia 26
CO - Colombia 25
IQ - Iraq 22
ZA - Sudafrica 21
CZ - Repubblica Ceca 19
MA - Marocco 17
AU - Australia 13
CH - Svizzera 11
CL - Cile 11
AZ - Azerbaigian 10
IL - Israele 10
VE - Venezuela 10
LT - Lituania 9
PH - Filippine 9
IR - Iran 8
NZ - Nuova Zelanda 8
PE - Perù 8
TH - Thailandia 8
TN - Tunisia 8
KE - Kenya 7
PY - Paraguay 7
NP - Nepal 6
UZ - Uzbekistan 6
AE - Emirati Arabi Uniti 5
BJ - Benin 5
BO - Bolivia 5
EG - Egitto 5
JO - Giordania 5
KG - Kirghizistan 5
SA - Arabia Saudita 5
AL - Albania 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
KZ - Kazakistan 4
MK - Macedonia 4
RO - Romania 4
SN - Senegal 4
UY - Uruguay 4
BH - Bahrain 3
BY - Bielorussia 3
CR - Costa Rica 3
DZ - Algeria 3
ET - Etiopia 3
MY - Malesia 3
BG - Bulgaria 2
EU - Europa 2
GA - Gabon 2
GI - Gibilterra 2
GT - Guatemala 2
HN - Honduras 2
LK - Sri Lanka 2
LV - Lettonia 2
NG - Nigeria 2
NI - Nicaragua 2
TW - Taiwan 2
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BN - Brunei Darussalam 1
BW - Botswana 1
CG - Congo 1
CI - Costa d'Avorio 1
CV - Capo Verde 1
CY - Cipro 1
GE - Georgia 1
GY - Guiana 1
HR - Croazia 1
IS - Islanda 1
JM - Giamaica 1
Totale 26.336
Salva come PNG Salva come JPEG
Città #
Moscow 3.126
Dublin 1.221
San Jose 961
Singapore 860
Hong Kong 848
Santa Clara 784
Chandler 669
Jacksonville 563
Ashburn 328
Seoul 294
Beijing 221
Ho Chi Minh City 211
Naples 197
New York 184
Hanoi 164
Princeton 163
Hefei 160
Dallas 154
Council Bluffs 140
Bremen 138
Roxbury 129
Los Angeles 124
Medford 121
Ann Arbor 120
Munich 103
The Dalles 93
Bengaluru 84
Caserta 79
São Paulo 75
Wilmington 72
Boardman 59
Milan 53
Nanjing 48
Cambridge 47
Chicago 46
Des Moines 44
San Mateo 43
Da Nang 40
Woodbridge 38
Turku 37
Haiphong 36
Amsterdam 34
Elora 34
Napoli 34
Nuremberg 33
Brussels 29
Warsaw 27
Brooklyn 26
Rio de Janeiro 26
Houston 25
Atlanta 22
Dong Ket 22
Orem 22
Shanghai 22
Tianjin 22
Aversa 21
Rome 20
Tokyo 20
Hải Dương 19
Vienna 19
Montreal 18
Falkenstein 17
Frankfurt am Main 17
Mountain View 17
Brno 16
Manchester 16
Brasília 15
Columbus 15
Nanchang 15
Norwalk 15
Chennai 14
Helsinki 14
London 14
San Francisco 14
Hangzhou 13
Jakarta 13
Lappeenranta 13
Rawalpindi 13
Thái Bình 13
Belo Horizonte 12
Bogotá 12
Changsha 12
Jinan 12
Madrid 12
Boston 11
Düsseldorf 11
Ercolano 11
Istanbul 11
Piscataway 11
Seattle 11
Baku 10
Curitiba 10
Guangzhou 10
Memphis 10
Mumbai 10
Toronto 10
Buffalo 9
Cape Town 9
Guayaquil 9
Hillsboro 9
Totale 13.858
Salva come PNG Salva come JPEG
Nome #
Comparative study of NGS platform ion torrent personal genome machine and therascreen rotor-gene Q for the detection of somatic variants in cancer. 253
Beyond N staging in colorectal cancer: Current approaches and future perspectives 226
Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells 211
ONCOLOGIA MEDICA 209
AXL is an oncotarget in human colorectal cancer 196
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 196
Antitumor efficacy of Kisspeptin in human malignant mesothelioma cells 193
Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures 189
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 187
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 185
A Novel EGFR Targeted Immunotoxin Based on Cetuximab and Type 1 RIP Quinoin Overcomes the Cetuximab Resistance in Colorectal Cancer Cells 184
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 184
A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer 181
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 179
Antitumor activity of bortezomib in human cancer cells with acquired resistance to anti-epidermal growth factor receptor tyrosine kinase inhibitors 178
Metabolomic approach for a rapid identification of natural products with cytotoxic activity against human colorectal cancer cells 178
A preliminary study for quantitative assessment with HFUS (High-frequency ultrasound) of nodular skin melanoma breslow thickness in adults before surgery: Interdisciplinary team experience 177
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 176
Microsatellite Status Detection in Gastrointestinal Cancers: PCR/NGS Is Mandatory in Negative/Patchy MMR Immunohistochemistry 176
Antitumor activity of sorafenib in human cancer cell lines with acquired resistance to EGFR and VEGFR tyrosine kinase inhibitors. 168
Small Bowel Metastasis in a Stage IV Melanoma Patient: A Report of Multimodal Approach 165
Antitumor activity of ZD6474, a vascular endothelial growth factor-2 and epidermal growth factor receptor small molecule tyrosine kinase inhibitor, in combination with SC-236, a cyclooxygenase-2 inhibitor 164
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors 164
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 164
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 164
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 164
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 163
AXL is a predictor of poor survival and of resistance to anti-EGFR therapy in RAS wild-type metastatic colorectal cancer 163
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 162
Activity and molecular targets of pioglitazone via blockade of proliferation, invasiveness and bioenergetics in human NSCLC 162
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 162
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 161
Cytologic diagnosis of metastatic melanoma by FNA: A practical review 161
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 160
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 160
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 160
Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer 155
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 155
antitumor activity of zd6474, a VEGFR-2 and EGFR small molecule tyrosine kinase inhibitor in combination with SC-236, a cicloxigenase-2 inhibitor 154
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 154
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 153
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 153
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 152
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 152
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 151
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 150
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 148
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 147
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 147
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 147
Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy 147
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 147
Pimasertib hydrochloride 146
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 145
Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors 144
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 143
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 142
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 141
Antiangiogenic drugs in non small cell lung cancer treatment 141
Farmacogenomica e cancro colorettale 139
Hepatoid carcinoma colliding with a liposarcoma of the left colon serosa presenting as an abdominal mass 139
Antitumor Efficacy of Dual Blockade of EGFR Signaling by Osimertinib in Combination With Selumetinib or Cetuximab in Activated EGFR Human NCLC Tumor Models 139
The JAK-STAT Pathway as a Therapeutic Strategy in Cancer Patients with Immune Checkpoint Inhibitor-Induced Colitis: A Narrative Review 138
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 136
To Get the Most out of the Least: BRAF Molecular Evaluation in Melanoma Metastases on Cell Suspension from Fine Needle Aspiration Cytology Needle Rinses 136
Intrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells. 136
The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors 136
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 134
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 134
Synergistic Antitumor Activity of Sorafenib in Combination with Epidermal Growth Factor Receptor Inhibitors in Colorectal and Lung Cancer Cells 133
SMO Gene Amplification and Activation of the Hedgehog Pathway as Novel Mechanisms of Resistance to Anti-Epidermal Growth Factor Receptor Drugs in Human Lung Cancer 133
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 133
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 132
Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines 130
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 130
TRASTUZUMAB RESISTANCE IN BREAST CANCER 129
Long-term Clinical Outcome of Trastuzumab and Lapatinib for HER2-positive Metastatic Colorectal Cancer 129
Application of CytoMatrix for the diagnosis of melanoma metastases on FNA cytology samples: Performance of a novel cell block method 127
Immunotherapy in advanced anal cancer: Is the beginning of a new era? 127
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 126
Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases 126
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 126
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 126
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 125
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 125
Targeting EGFR in Pancreatic Cancer Treatment. 124
Evaluation of second-line anti-VEGF after first-line anti-EGFR based therapy in RAS wild-type metastatic colorectal cancer: The multicenter “SLAVE” study 124
Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis 123
Adipose-tumor crosstalk in colorectal cancer: Identifying (Epi)genetic biomarkers for tumor progression and cachexia 123
Prevention of cardiovascular complications in elderly cancer patients 123
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next generation sequencing: findings from the CAPRI-GOIM trial. 123
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 123
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 122
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 122
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 122
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 122
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 121
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 120
Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer. 120
Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance. 120
Totale 15.095
Salva come PNG Salva come JPEG
Categoria #
all - tutte 94.195
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 94.195
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.106 0 26 27 25 340 25 37 35 57 90 120 324
2022/20232.567 255 56 46 237 283 233 10 158 1.150 14 71 54
2023/20241.111 102 49 40 67 329 171 33 33 21 16 86 164
2024/20253.522 61 93 47 139 527 462 453 328 466 379 308 259
2025/202615.251 609 716 748 734 1.213 8.144 809 791 642 416 260 169
2026/2027467 139 328 0 0 0 0 0 0 0 0 0 0
Totale 26.866